MTEM
Closed
Molecular Templates Inc
0.0001
0.0000 (0.00%)
Last Update: 20 May 2025 16:30:00
Yesterday: 0.0001
Day's Range: 0.0001 - 0.0001
Send
sign up or login to leave a comment!
When Written:
0.43
Molecular Templates Inc. is a clinical-stage biopharmaceutical company that focuses on developing targeted biologic therapeutics for cancer and other diseases. The company's proprietary platform, Engineered Toxin Bodies (ETBs), enables the creation of novel targeted therapeutics that combine the specificity of antibodies with the potency of toxins.
Molecular Templates' lead product candidate, MT-3724, is an ETB targeting CD20, a protein expressed on the surface of B-cell lymphomas. MT-3724 is currently being evaluated in a Phase 2 clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
The company is also developing ETBs targeting other cancer targets, including HER2, PD-L1, and CTLA-4, as well as non-cancer targets, such as viral infections. Molecular Templates has partnerships with Takeda Pharmaceutical Company and Vertex Pharmaceuticals to develop ETBs for various indications.
Molecular Templates was founded in 2009 and is headquartered in Austin, Texas.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Molecular Templates' lead product candidate, MT-3724, is an ETB targeting CD20, a protein expressed on the surface of B-cell lymphomas. MT-3724 is currently being evaluated in a Phase 2 clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.
The company is also developing ETBs targeting other cancer targets, including HER2, PD-L1, and CTLA-4, as well as non-cancer targets, such as viral infections. Molecular Templates has partnerships with Takeda Pharmaceutical Company and Vertex Pharmaceuticals to develop ETBs for various indications.
Molecular Templates was founded in 2009 and is headquartered in Austin, Texas.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








